Michael Heffernan was already the head of a biotech company focused on chronic pain, called Collegium Pharmaceutical, which he successfully brought public in 2015. But when his wife was diagnosed with ovarian cancer, he knew that was his next mission. Heffernan’s wife is doing well — but unfortunately, that isn’t the case for most patients, […]

OQL011, for cancer therapy induced skin toxicity, demonstrated a tolerable safety and acceptable efficacy profile, according to topline results of part 1 of the phase 2 NOVA-II trial reported by OnQuality Pharmaceuticals. OQL011 is an ointment designed to treat hand-foot skin reaction (HFSR) which is a common adverse event of tyrosine kinase inhibitors, including VEGF […]

In phase 1 and 2 studies (NCT04524351), respectively, people with early Alzheimer disease (AD) and early Parkinson disease (PD) who were treated with posiphen (ANVS401; Annovis, Berwyn, PA) had statistically significant clinical improvements. Changes in biomarkers of neurodegeneration and neuroinflammation were also observed. Posiphen is an orally administered translational inhibitor of neurotoxic proteins that form […]